New combo aims to stall advanced stomach cancer
NCT ID NCT07070466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) in people with advanced HER2-negative stomach or esophagus cancer that has not been treated before. The goal is to see if the combination can keep the cancer from growing for at least 6 months. About 40 participants will receive the treatment, and researchers will monitor side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
UCLA
RECRUITINGSanta Monica, California, 90404, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can switching cancer therapy early extend life in stomach cancer?
- Drug cocktail aims to shrink Hard-to-Treat stomach cancers
- Personalized radiation pulses could boost esophageal cancer treatment
- Can a condensed radiation blast plus chemo keep esophageal cancer at bay?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Music may soothe pain at the genetic level after cancer surgery